Brivaracetam

GPTKB entity

Statements (54)
Predicate Object
gptkbp:instance_of gptkb:Antihero
gptkbp:approves gptkb:2016
gptkb:FDA
gptkbp:atccode N03 AX20
gptkbp:available_on gptkb:Software_Solutions
gptkb:tablet
injection
gptkbp:brand gptkb:Briviact
gptkbp:casnumber 357336-20-0
gptkbp:category gptkb:unknown
gptkb:C
gptkbp:chemical_formula C11 H14 N2 O3
gptkbp:class anticonvulsants
gptkbp:clinical_trial Phase III
gptkbp:clinical_use monotherapy
adjunctive therapy
gptkbp:contraindication hypersensitivity
gptkbp:defines UCB 34714
gptkbp:developed_by gptkb:UCB_Pharma
gptkbp:dosage_form oral tablet
oral solution
IV injection
gptkbp:duration short-term
long-term
gptkbp:excretion urine
https://www.w3.org/2000/01/rdf-schema#label Brivaracetam
gptkbp:indication partial-onset seizures
gptkbp:interacts_with gptkb:beer
oral contraceptives
other antiepileptic drugs
gptkbp:lifespan 8 to 9 hours
gptkbp:marketed_as gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:United_States
gptkbp:mechanism_of_action SV2 A binding
gptkbp:metabolism liver
gptkbp:pharmacokinetics linear pharmacokinetics
gptkbp:research_areas clinical trials
neurology
pharmacology
gptkbp:route_of_administration oral
intravenous
gptkbp:side_effect dizziness
fatigue
nausea
irritability
drowsiness
gptkbp:structure pyrrolidine derivative
gptkbp:targets synaptic vesicle protein 2 A
gptkbp:used_for gptkb:epilepsy
gptkbp:bfsParent gptkb:Briviact
gptkbp:bfsLayer 7